[Articles] Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial

Journal content Created on 02 Jun 2026 The Lancet Oncology

• Details
• • All feed content
  • My feed content